objective To compare the performance of two novel recombinant antigens (EgP29, 2B2t) with imaging in a well-defined cohort of surgically treated cystic echinococcosis (CE) patients to determine whether serology reflects surgical cure as defined by imaging.
Introduction
In cystic echinococcosis (CE), diagnosis, cyst staging, therapeutic approach and follow-up rely on imaging [1] . Cyst staging is based on the WHO cyst classification defined by ultrasound (US) features, which can largely be reproduced by magnetic resonance imaging (MRI) but less so by computed tomography (CT) [2] . Given the rare access to imaging in the regions most affected (South America, northern and eastern Africa, Eurasia) and for patient convenience, replacement of imaging by serological point-of-care test to monitor primary cure and recurrences after surgical interventions is desirable.
Over the past decades, numerous native and recombinant antigens have been evaluated [3] [4] [5] , and the search for suitable antigens is ongoing, but only few of them have been tested in follow-up studies. A recent thorough review on this can be found in Siles-Lucas et al. [6] . Loss of specific antibodies after successful surgical treatment in patients has been reported against the recombinant antigens B, B2t, P29 and HSP20 [7] [8] [9] [10] . Nevertheless, further studies are needed to address the usefulness of these or other recombinant antigens in the follow-up of CE patients.
We tested two recombinant antigens, EgP29 and the novel 2B2t [7, 11] , in a clinically well-defined patient cohort to address the following question: Does serology reproduce surgical cure as defined by imaging?
Methods
The Clinical Tropical Medicine Section at Heidelberg University Hospital has been running an interdisciplinary clinic for echinococcosis in cooperation with the Department of Diagnostic and Interventional Radiology with weekly radiological conferences, the Department of Surgery, the Department of Thoracic Surgery, the Interdisciplinary Endoscopy Center and the Department of Parasitology since 1999. Clinical, serological and imaging data are systematically collected and entered into a database at each patient visit. Serum samples are stored at À80°C.
Patients not meeting inclusion criteria 28 surgically treated patients 39 patients referred to another hospital after surgery 41 medical treatment 12 percutaneous treatment 67 "watch & wait" management 223 patients in CE database Patients meeting inclusion criteria 36 patients treated surgically and meeting inclusion criteria Figure 1 Selection of subjects from the Heidelberg CE patient cohort. The database was screened for CE-confirmed patients eligible for inclusion in this study. The Ethics Committee of the University of Heidelberg (S126/2010) approved the retrospective analysis of patient data. All patient data we analysed were anonymised.
Inclusion criteria
Surgically treated patients without residual cysts after surgery and a minimum of three post-surgical follow-up visits; at least two serum samples, one before surgery, up to one year after surgery and one thereafter.
Serum samples were allocated to three time periods:
• Peri-surgical: before surgery until <1 year after surgery, the rationale being that a positive serological response at any time point during this period is a valid starting point for long-term post-surgical serological follow-up
• Early post-surgical follow-up: ≥1 year and <5 years after surgery
• Late post-surgical follow-up: ≥5 years after surgery
Serological tests
Serum samples were examined by ELISA to measure specific IgG and IgG4 [12, 13] antibodies against both the 2B2t [8] and the EgP29 [9, 11] antigens. Serological testing was performed at the Instituto de Recursos Naturales y Agrobiolog ıa de Salamanca (IRNASA-CSIC), Salamanca, Spain. Of all patients, the initial peri-surgical and the follow-up serum samples were tested in parallel. The measurements were blinded for clinical patient outcomes. The serological index (SI) was calculated for each absorbance in each plate using the following formula: [(NC-S)/(NC-PC)] 9 100, where NC and PC represent negative and positive controls, respectively, and S stands for each serum. Negative control consisted of a pool of 10 sera from healthy donors with an optical density (OD) in the ELISA of 0.1-0.2; positive control was a pool of 10 sera from CE patients with an OD in the ELISA of 0.4-0.5. Negative and positive controls were placed in duplicate in each plate.
The best cut-off values for the antigens were determined by receiver operating characteristic (ROC) analysis. To determine these values, sera from CE patients were considered true positives, while sera from healthy donors (n = 50, kindly donated by the University Hospital, Salamanca, Spain) were considered true negatives. The SI cut-off value calculated by ROC was 50 for the tested antigens (data not shown).
'Serological cure' was defined as seroconversion from a peri-surgically positive to a negative result at follow-up.
Reference standard
Cyst stages according to the WHO classification [14] were determined by US, MRI or CT imaging. Surgical cure was defined as no new growth detected by imaging at the site where the cyst had been surgically removed and as no new lesions elsewhere due to spillage of hydatid fluid during surgery over a 10-year observation period.
Statistical analysis
We used a hierarchical linear regression model to examine the course of antibody levels (determined as SI) over time for each patient. The model included a patient-specific (random) intercept. The time (in years) to reach the negativity threshold (SI = 50) and its standard error were then calculated for each patient using the patient-specific intercept and a slope parameter describing the decline of the antibody levels. In a second step, a meta-analysis of the patient-specific estimates of the time to negativity was performed using the metan command in Stata. All statistical analyses were performed using Stata/IC 13.1 (StataCorp, Texas).
Results

Baseline data
Of the 223 patients entered into the database, 114 were males and 109 were females. The median age was 37.6 years (6.7-82.2). Further treatment characteristics of the cohort are detailed in Figure 1 .
Of the 64 surgically treated patients of the Heidelberg CE patient cohort, 36 fulfilled the inclusion criteria. 6.9 AE 2.9 years (2.2-14.1). Cyst localisation and WHO cyst stage are summarised in Table 1 . Thirteen patients were of Turkish origin, 10 patients were from East or Southern Europe, five from the former CIS states, four from Germany and four from the Middle East region. In total, 111 serum samples were available: two from 10 patients, three from 13 patients and four from 13 patients. A significant proportion of patients tested with recombinant antigen ELISAs could not be included in post-surgery follow-up analysis because their sera did not show a positive response to these antigens at the beginning of post-surgical monitoring (Table 2) . At all time points at which serum samples were available and tested, imaging revealed no new growth at the site where the cyst had been surgically removed and showed no new lesion elsewhere except in two patients. Neither of the two patients (Figures 2 and 3) was eligible for serological follow-up because they did not respond to the test at the beginning of post-surgical monitoring. Additionally, they remained negative at the time of recurrence as identified by imaging (Figures 2  and 3) .
Analysis of time to seronegativity
A random intercept model was applied to our patient data to examine the course of antibody levels (determined as SI) over time. The pooled estimates for time to seronegativity (defined as SI = 50) for the ELISA tests employing the novel recombinant antigens were as follows: 2B2t-ELISA 3.92 years; 2B2t-IgG4-ELISA 4.60 years; EgP29-ELISA 3.94 years; EgP29-IgG4-ELISA 2.55 years. The patient-specific estimates varied widely with values between 1.97 and 9.82 years in the 2B2t-ELISA; 3.08 and 7.20 years in the 2B2t-IgG4-ELISA; 2.83 and 8.02 years in the EgP29-ELISA; and 1.26 and 14.73 years in the EgP29-IgG4-ELISA (Figures 4-7 
Discussion
We have engaged two novel recombinant antigens for patient follow-up after surgery (2B2t-Ag and EgP29-Ag).
After surgical treatment, antibodies to the recombinant antigens 2B2t and EgP29 become indeed negative in the majority of patients who do not show (as detected by imaging) new growth at the site where the CE cysts had been surgically removed or new lesions due to spillage of hydatid fluid during surgery. This effect is most clearly seen ≥5 years after surgery. However, the major drawback is the fact that only around half of the surgically treated and CE-confirmed patients of our cohort were at all responsive to the novel test antigens at the beginning of post-surgical monitoring. Additionally, the only two recurrences in our cohort were not eligible for serological follow-up analysis because they did not respond to the recombinant test antigens in the peri-surgical period. When tested at the time of relapse (as observed by imaging), they remained negative; our recombinant antigens thus failed to detect disease recurrence after surgery (Figures 2 and 3) . Although not representative, this result is not surprising. Low sensitivity is a limitation of current serological tests for the detection of early cyst stages, that is new cyst growth [14, 15] . On the contrary, sensitivity of imaging for CE cysts is high, and liver lesions at a diameter of 5 mm can already be detected [16] . Imaging provides the additional advantage of classifying CE cysts into five distinct stages. Stage-specific features enhance the specificity of imaging.
The small sample size is a limitation of the study; however, our CE patient cohort provides carefully documented long-term data on both serology and imaging, allowing evaluation of new diagnostic tests against the current gold standard [17] .
In summary, the recombinant antigens tested become negative in cured patients. Compared to imaging, however, they are still less suited for post-surgical followup of CE patients. This is due to the fact that a significant proportion of patients in our cohort are not responsive to these antigens in the peri-surgical period, the starting point of serological follow-up after surgery. Equally, in our cohort, the antigens do not appear to be sensitive enough to detect recurrences. Further research is required to better understand the cyst stage-specific expression of antigens and, very importantly, if and when they are presented to the host immune system.
For the time being, initial diagnosis of CE, follow-up after interventions and early detection of recurrences remain the realm of imagination.
